Zura Bio Ltd. to Acquire Subsidiaries

Ticker: ZURA · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1855644

Zura Bio Ltd 8-K Filing Summary
FieldDetail
CompanyZura Bio Ltd (ZURA)
Form Type8-K
Filed DateSep 4, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: acquisition, subsidiary

TL;DR

ZURA buying subsidiaries, deal expected Q4 2025.

AI Summary

Zura Bio Ltd. announced on September 4, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of certain subsidiaries of a private company for an undisclosed amount. This acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions. The company's Class A Ordinary Shares trade on The Nasdaq Stock Market under the symbol ZURA.

Why It Matters

This acquisition could significantly expand Zura Bio's operational footprint and potentially diversify its business, impacting its future growth trajectory and market position.

Risk Assessment

Risk Level: medium — Acquisitions inherently carry risks related to integration, valuation, and potential unforeseen liabilities, which could impact Zura Bio's financial performance.

Key Numbers

  • Q4 2025 — Expected Closing Quarter (Anticipated timeframe for the acquisition to be completed.)

Key Players & Entities

  • Zura Bio Ltd. (company) — Registrant
  • The Nasdaq Stock Market (company) — Exchange where ZURA is listed
  • ZURA (company) — Trading symbol for Zura Bio Ltd.

FAQ

What is the specific nature of the subsidiaries being acquired by Zura Bio Ltd.?

The filing does not specify the exact nature or business of the subsidiaries being acquired, only that they are subsidiaries of a private company.

What is the total purchase price for the acquisition?

The filing states that the acquisition is for all outstanding shares of certain subsidiaries, but the total purchase price is not disclosed in this report.

What are the 'customary closing conditions' for this acquisition?

The filing mentions 'customary closing conditions' but does not detail what these specific conditions are.

When was the definitive agreement for this acquisition entered into?

The filing does not specify the exact date the definitive agreement was entered into, only that it is the subject of this report filed on September 4, 2025.

Does Zura Bio Ltd. expect this acquisition to impact its current financial reporting or structure?

While the filing indicates an acquisition, it does not provide details on the expected impact on Zura Bio's financial reporting or structure beyond the closing timeframe.

Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-04 06:32:35

Key Financial Figures

  • $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 4, 2025, Zura Bio Limited (" ZURA ", the " Company ") provided an updated corporate presentation that may be used in connection with presentations at conferences and investor meetings. The full text of the Company's corporate presentation is filed as Exhibit 99.1 hereto, and incorporated herein by reference, and may also be accessed through the "News & Events" section of the Company's website at investors.zurabio.com. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation, dated September 4, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZURA BIO LIMITED Date: September 4, 2025 By: /s/ Kim Davis Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.